US patients face insurance cuts to GLP-1 weight‑loss drugs

Insurance plans across the United States are ending coverage for GLP‑1 medications used for weight loss, including Zepbound and Wegovy. Researchers at GoodRx estimate that about 12 million people were on plans that stopped covering each drug between 2025 and 2026.

Patients like Deborah Finley, a 50‑year‑old from Lodi, California, discovered that her insurer would still cover Zepbound when it is prescribed for related conditions such as obstructive sleep apnea or metabolic‑associated fatty liver disease (MASH). Health experts advise reviewing policy fine print, filing prior‑authorization requests, and appealing denials with detailed medical evidence. Dr. Caleb Alexander of Johns Hopkins and Dr. Catherine Varney of UVA Health stress that appeals can succeed when patients document qualifying health issues and, if needed, seek assistance in drafting appeals.